SZN 8143
Alternative Names: SZN-8143Latest Information Update: 03 Dec 2024
Price :
$50 *
At a glance
- Originator Surrozen
- Class Eye disorder therapies; Trispecific antibodies
- Mechanism of Action FZD4 protein stimulants; Interleukin 6 inhibitors; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Age-related macular degeneration; Diabetic macular oedema; Retinal oedema
Most Recent Events
- 13 Nov 2024 New profile triggered via media release: 9429267
- 06 Nov 2024 Preclinical trials in Age-related macular degeneration in USA (Parenteral) prior to November 2024 (Surrozen pipeline, November 2024)
- 06 Nov 2024 Preclinical trials in Diabetic macular oedema in USA (Parenteral) prior to November 2024 (Surrozen pipeline, November 2024)